The estimated Net Worth of Richard Bryan Riggsbee is at least $11.1 Milion dollars as of 1 December 2023. Richard Riggsbee owns over 30,000 units of Myriad Genetics stock worth over $7,668,819 and over the last 10 years Richard sold MYGN stock worth over $3,449,035.
Richard has made over 8 trades of the Myriad Genetics stock since 2019, according to the Form 4 filled with the SEC. Most recently Richard sold 30,000 units of MYGN stock worth $572,700 on 1 December 2023.
The largest trade Richard's ever made was selling 30,000 units of Myriad Genetics stock on 1 December 2023 worth over $572,700. On average, Richard trades about 3,020 units every 33 days since 2014. As of 1 December 2023 Richard still owns at least 291,812 units of Myriad Genetics stock.
You can see the complete history of Richard Riggsbee stock trades at the bottom of the page.
Richard's mailing address filed with the SEC is 320, Wakara Way, U of U Research Park, Salt Lake City, Salt Lake County, Utah, 84108, United States.
Over the last 22 years, insiders at Myriad Genetics have traded over $51,783,466 worth of Myriad Genetics stock and bought 61,160 units worth $1,252,955 . The most active insiders traders include Jerry S Lanchbury, Peter D Meldrum oraz Arthur H Jr Hayes. On average, Myriad Genetics executives and independent directors trade stock every 18 days with the average trade being worth of $563,312. The most recent stock trade was executed by Heinrich Dreismann on 9 September 2024, trading 10,000 units of MYGN stock currently worth $270,500.
myriad genetics inc., is a leading personalized medicine company dedicated to being a trusted advisor transforming patient lives worldwide with pioneering molecular diagnostics. myriad discovers and commercializes molecular diagnostic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major medical specialties where molecular diagnostics can significantly improve patient care and lower healthcare costs. myriad is focused on three strategic imperatives: maintaining leadership in an expanding hereditary cancer market, diversifying its product portfolio through the introduction of new products and increasing the revenue contribution from international markets. for more information on how myriad is making a difference, please visit the company's website: www.myriad.com.
Myriad Genetics executives and other stock owners filed with the SEC include: